Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes
Open Access
- 9 April 2025
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 15 (4) , 255
Abstract
Background/Objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed drugs for NAFLD by leveraging disease–disease relationships and drug–target data from the BioSNAP database. Methods: A bipartite network was constructed between drugs and their target genes, followed by the application of the BiClusO bi-clustering algorithm to identify high-density clusters. Clusters with significant associations with NAFLD risk genes were considered to predict potential drug candidates. Another set of candidates was determined based on disease similarity. Results: A novel ranking methodology was developed to evaluate and prioritize these candidates, supported by a comprehensive literature review of their effectiveness in NAFLD treatment. Conclusions: This research demonstrates the potential of drug repurposing to accelerate the development of therapies for NAFLD, offering valuable insights into novel treatment strategies for complex diseases.Keywords
Funding Information
- Grants-in-Aid for Scientific Research of the Japanese Government (25K15338, 20K12043)
This publication has 34 references indexed in Scilit:
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat dietScientific Reports, 2024
- Lifestyle interventions in nonalcoholic fatty liver diseaseNature Reviews Gastroenterology & Hepatology, 2023
- Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in miceDiabetologia, 2023
- The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resourceNucleic Acids Research, 2022
- Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?Metabolism, 2022
- DPClusSBO: An integrated software for clustering of simple and bipartite graphsSoftwareX, 2021
- The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trialComplementary Therapies in Medicine, 2020
- Fructose and sugar: A major mediator of non-alcoholic fatty liver diseaseJournal of Hepatology, 2018
- Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trialsNutrition, 2015
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004